Zephyr Health (300723.SZ): The innovative drug AR882 has not yet achieved market sales and has not generated any sales revenue.

Wisdom Financial News APP reported that One Plant (300723.SZ) announced a stock price abnormality notice. The company stated that the cooperation to develop the innovative drug AR882 still needs to undergo phase III clinical trials both domestically and internationally, and must be approved by the drug regulatory department before it can be marketed. Whether it can obtain final approval from the regulatory authorities, be approved for listing, and the timing of listing are uncertain. AR882 has not yet been marketed and has not generated any sales revenue, so it will not have a significant impact on the company's recent performance.